Coinbase Global Inc (COIN)vsGlaxoSmithKline PLC ADR (GSK)
COIN
Coinbase Global Inc
$201.16
+4.25%
FINANCIAL SERVICES · Cap: $50.96B
GSK
GlaxoSmithKline PLC ADR
$50.41
-0.18%
HEALTHCARE · Cap: $101.38B
Smart Verdict
WallStSmart Research — data-driven comparison
GlaxoSmithKline PLC ADR generates 376% more annual revenue ($32.78B vs $6.88B). COIN leads profitability with a 18.3% profit margin vs 17.8%. GSK appears more attractively valued with a PEG of 0.50. GSK earns a higher WallStSmart Score of 66/100 (B-).
COIN
Buy60
out of 100
Grade: C
GSK
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for COIN.
Margin of Safety
-3.1%
Fair Value
$56.71
Current Price
$50.41
$6.30 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 430.6% YoY
Large-cap with strong market position
Growing faster than its price suggests
Growing faster than its price suggests
Every $100 of equity generates 41 in profit
Strong operational efficiency at 36.3%
Large-cap with strong market position
Attractively priced relative to earnings
Areas to Watch
Distress zone — elevated risk
Weak financial health signals
Premium valuation, high expectations priced in
Revenue declined 22.2%
1.5% revenue growth
Elevated debt levels
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : COIN
The strongest argument for COIN centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 18.3% and operating margin at 11.3%. PEG of 0.78 suggests the stock is reasonably priced for its growth.
Bull Case : GSK
The strongest argument for GSK centers on PEG Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 17.8% and operating margin at 36.3%. PEG of 0.50 suggests the stock is reasonably priced for its growth.
Bear Case : COIN
The primary concerns for COIN are Altman Z-Score, Piotroski F-Score, P/E Ratio. A P/E of 70.9x leaves little room for execution misses.
Bear Case : GSK
The primary concerns for GSK are Revenue Growth, Debt/Equity, Altman Z-Score.
Key Dynamics to Monitor
COIN profiles as a declining stock while GSK is a value play — different risk/reward profiles.
COIN carries more volatility with a beta of 3.38 — expect wider price swings.
GSK is growing revenue faster at 1.5% — sustainability is the question.
GSK generates stronger free cash flow (698M), providing more financial flexibility.
Bottom Line
GSK scores higher overall (66/100 vs 60/100), backed by strong 17.8% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Coinbase Global Inc
FINANCIAL SERVICES · FINANCIAL DATA & STOCK EXCHANGES · USA
Coinbase Global, Inc. provides financial infrastructure and technology for the crypto economy. The company is headquartered in Wilmington, Delaware.
Visit Website →GlaxoSmithKline PLC ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK, US and internationally. The company is headquartered in Brentford, the United Kingdom.
Compare with Other FINANCIAL DATA & STOCK EXCHANGES Stocks
Want to dig deeper into these stocks?